Donald E Thornton
Overview
Explore the profile of Donald E Thornton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho B, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, et al.
Blood
. 2015 Jun;
126(2):222-32.
PMID: 26031918
Targeting the stromal cell-derived factor 1α (SDF-1α)/C-X-C chemokine receptor type 4 (CXCR4) axis has been shown to be a promising therapeutic approach to overcome chemoresistance in acute myeloid leukemia (AML)....
2.
Butowski N, Chang S, Lamborn K, Polley M, Pieper R, Costello J, et al.
Neuro Oncol
. 2011 Sep;
13(12):1331-8.
PMID: 21896554
This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma. Adults with newly diagnosed disease and Karnofsky performance status...
3.
Butowski N, Chang S, Lamborn K, Polley M, Parvataneni R, Hristova-Kazmierski M, et al.
Neuro Oncol
. 2010 Feb;
12(6):608-13.
PMID: 20156802
We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when...
4.
Wick W, Puduvalli V, Chamberlain M, van den Bent M, Carpentier A, Cher L, et al.
J Clin Oncol
. 2010 Feb;
28(7):1168-74.
PMID: 20124186
Purpose: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). Patients And Methods: Patients were randomly assigned...
5.
Carducci M, Musib L, Kies M, Pili R, Truong M, Brahmer J, et al.
J Clin Oncol
. 2006 Sep;
24(25):4092-9.
PMID: 16943527
Purpose: This phase I study was conducted to determine the recommended dose of enzastaurin, an oral protein kinase C beta (PKCbeta) inhibitor, for phase II trials. Secondary objectives were maximum-tolerated...
6.
Kutikova L, Bowman L, Chang S, Long S, Thornton D, Crown W
J Neurooncol
. 2006 Jun;
81(1):61-5.
PMID: 16773215
Objectives: To evaluate the economic burden of primary malignant brain tumors in a commercially insured population in the United States, and to identify the primary drivers of health care resource...